Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon

Although rifaximin is currently advised in managing symptomatic uncomplicated diverticular disease (SUDD) of the colon, no long-term data are available. This retrospective study assessed the outcome of a large cohort of patients with SUDD, treated with rifaximin, during an 8-year follow-up. The stud...

Full description

Saved in:
Bibliographic Details
Published in:Journal of investigative medicine 2019-04, Vol.67 (4), p.767-770
Main Authors: Di Mario, Francesco, Miraglia, Chiara, Cambiè, Ginevra, Violi, Alessandra, Nouvenne, Antonio, Franceschi, Marilisa, Brandimarte, Giovanni, Elisei, Walter, Picchio, Marcello, Tursi, Antonio
Format: Article
Language:English
Subjects:
Abdomen
Antibiotics
Chemotherapy
Colon
Colonoscopy
Consent
Gastroenterology
Irritable bowel syndrome
Pain
Probiotics
RNA polymerase
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although rifaximin is currently advised in managing symptomatic uncomplicated diverticular disease (SUDD) of the colon, no long-term data are available. This retrospective study assessed the outcome of a large cohort of patients with SUDD, treated with rifaximin, during an 8-year follow-up. The study group (group A) included 346 patients with SUDD (median age 64 years, IQR 58–69, 62.4% females), treated with rifaximin 800 mg/d for 7 days every month. The control group (group B) included 470 patients with SUDD (median age 65 years, IQR 59–74 years, 60.8% females), taking any other treatment on demand. Two symptoms (left lower abdominal pain and bloating) were assessed by a visual analog scale (VAS), graded from 0=no symptom to 10=the most severe symptom. Daily bowel movements were also reported. Median (IQR) VAS score for pain was 6 (5–7) in group A and 6 (6–7) in group B at baseline (p=0.109); at 8-year follow-up it was 3 (3–4) and 6 (5–7), respectively (p
ISSN:1081-5589
1708-8267
DOI:10.1136/jim-2018-000901